The original backbone of HER-Vaxx was generic as of 2023 - https://patents.google.com/patent/US7348010B2/en?assignee=Biolife+Science+Qld+Limited. The patent expiration in 2030, and the one in 2036 are iterations of the original where small changes have been made to the composition or delivery. Specifically, more recently using the CRM-197 carrier protein and water-in-oil adjuvant. The issue with small adjustments like this are patent contests for obviousness. These sound awfully similar, don't they. Which expires first? Which sounds more comprehensive?
"The present invention relates generally to a vaccine composition comprising fragments of the cancer - related protein Her2 / neu , methods of preparing such composition, and uses thereof for the prevention or treatment of a cancer characterized by the expression or over - expression of the Her2 / neu protein."
"The present invention relates to fusion peptides comprising fragments of the cancer-related protein Her2/neu, methods of preparing Such fusion peptides, Virosomes comprising Such fusion peptides, and uses of Such fusion peptides and/or Virosomes for the prevention, treatment and/or amelioration of a cancer characterized by expression or over-expression of the Her2/neu protein."
This adds an element of risk to an already risky situation. I mean, look at all the people in the standard of care chemotherapy arm who died before they could complete monotherapy. They must have been very sick. I wonder why they were left in the final analysis when none of the HER-Vaxx patients died within the dosing window. Removing them sure does change the impact. HER-Vaxx does next to nothing.
IMU Price at posting:
3.8¢ Sentiment: Sell Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)